Search

Your search keyword '"Non-small cell lung cancer -- Genetic aspects -- Drug therapy"' showing total 68 results
Start Over Descriptor "Non-small cell lung cancer -- Genetic aspects -- Drug therapy"
68 results on '"Non-small cell lung cancer -- Genetic aspects -- Drug therapy"'

51. Researchers at NTT Medical Center Tokyo Target Non-Small Cell Lung Cancer (Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report)

Subjects
Cancer treatment, Medical centers, Cancer research, Afatinib, Biochemistry, Small cell lung cancer -- Genetic aspects -- Drug therapy, Immunotherapy, Epidermal growth factors, Pembrolizumab, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Editors, Lung cancer, Health
Abstract

2019 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Oncology - Non-Small Cell Lung Cancer. According to news reporting [...]

Published
2019

52. FDA Approves Genentech's Rozlytrek entrectinib for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors

Subjects
United States. Food and Drug Administration, Cancer genetics -- Genetic aspects -- Drug therapy, Genes, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Biological products industry, Anopheles, Phenols (Class of compounds), Biotechnology, Tumors, Pediatrics, Biotechnology industries, Tyrosine, Editors, Child health, Lung cancer, Biotechnology industry, Biological sciences, Business
Abstract

2019 AUG 26 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that [...]

Published
2019

53. FDA Approves Genentech's Rozlytrek for People with ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors

Subjects
United States. Food and Drug Administration, Genentech Inc., Cancer genetics -- Genetic aspects -- Drug therapy, Genes, Tyrosine, Biotechnology industries, Small cell lung cancer -- Genetic aspects -- Drug therapy, Drug approval, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Biological products industry, Phenols (Class of compounds), Tumors, Pediatrics, Child health, Lung cancer, Chemistry
Abstract

M2 PHARMA-August 19, 2019-FDA Approves Genentech's Rozlytrek for People with ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors (C)2019 M2 COMMUNICATIONS - The US Food and [...]

Published
2019

54. Researchers at Southeast University Release New Data on Non-Small Cell Lung Cancer (Treatment of Uncommon Egfr Mutations In Non-small Cell Lung Cancer: New Evidence and Treatment)

Subjects
Cancer research, Afatinib, Biochemistry, Small cell lung cancer -- Genetic aspects -- Drug therapy, Immunotherapy, Epidermal growth factors, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Accounting, Editors, Lung cancer, Health
Abstract

2019 JUL 31 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in Oncology - Non-Small Cell Lung Cancer. According to news reporting [...]

Published
2019

55. Findings from Nicolaus Copernicus University in Torun Reveals New Findings on Cyclin B (Expression of Cyclin B1, D1 and K In Non-small Cell Lung Cancer H1299 Cells Following Treatment With Sulforaphane)

Subjects
Cyanates -- Health aspects, Cancer cells -- Genetic aspects -- Health aspects, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Gene expression -- Health aspects, Small cell lung cancer, Chemotherapy, Cancer treatment, Cancer research, Proteins, Peptides, Cancer prevention, Editors, Lung cancer, Biological sciences, Health
Abstract

2019 JUN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Current study results on Intracellular Signaling Peptides and Proteins - Cyclin B have been [...]

Published
2019

56. FDA approves new indication for Gilotrif(r) in EGFR mutation-positive NSCLC

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim Pharmaceuticals Inc., Epidermal growth factors, Pharmaceutical industry, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, General interest, News, opinion and commentary, Gilotrif (Medication) -- Labeling
Abstract

Ridgefield, CT: Boehringer Ingelheim has issued the following news release: Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) [...]

Published
2018

57. Pfizer Gets Positive CHMP Opinion for Vizimpro for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

Subjects
United States. Food and Drug Administration, Pfizer Inc., Pharmaceutical industry, Small cell lung cancer -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Lung cancer, Marketing, Epidermal growth factors, Business, Business, international, Telecommunications industry, European Union, European Union. European Commission, Vizimpro (Medication)
Abstract

Pfizer reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro (dacomitinib) 45 mg, as monotherapy, [...]

Published
2019

58. Jilin University Reports Findings in Lung Cancer (Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report)

Subjects
Cancer treatment, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Osimertinib, Epidermal growth factors, Genetic research, Afatinib, Gene mutation, Small cell lung cancer, Editors, Cancer research, Adenocarcinoma, Lung cancer, Genes, Anopheles, Criminal investigation, Business, Health, Health care industry
Abstract

2019 JAN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators discuss new findings in Oncology - Lung Cancer. According to news reporting from Changchun, [...]

Published
2019

59. MultiVir Reports Reversal of Immunotherapy Resistance by Tumor Suppressor Immune Gene Therapy

Subjects
Cancer treatment, Cancer genetics -- Genetic aspects -- Drug therapy, Gene therapy, Genes, Tumors -- Genetic aspects -- Drug therapy, Immunotherapy, Squamous cell carcinoma -- Genetic aspects -- Drug therapy, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Biotechnology industry, Health, Science and technology
Abstract

2018 FEB 5 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- MultiVir Inc. presented updated data at the annual ASCO-SITC Clinical Immuno-Oncology Symposium demonstrating [...]

Published
2018

60. Reports from Department of Respiratory Medicine Advance Knowledge in Brain Metastasis (Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation)

Subjects
Surgery, Respiratory system agents, Medical research, Epidermal growth factors, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Health, Health care industry
Abstract

2018 JAN 28 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Researchers detail new data in Brain Diseases and Conditions - Brain [...]

Published
2018

61. Boehringer announces expanded indication for Gilotrif for NSCLC patients whose tumors have certain EGFR mutations

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH, Respiratory system agents, Tumors -- Genetic aspects -- Drug therapy, Pharmaceutical industry, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Chemistry, Gilotrif (Medication)
Abstract

M2 PHARMA-January 17, 2018-Boehringer announces expanded indication for Gilotrif for NSCLC patients whose tumors have certain EGFR mutations (C)2018 M2 COMMUNICATIONS Pharmaceutical company Boehringer Ingelheim reported on Tuesday the receipt [...]

Published
2018

62. Boehringer announces expanded indication for Gilotrif for NSCLC patients whose tumors have certain EGFR mutations

Subjects
United States. Food and Drug Administration, Boehringer Ingelheim GmbH, Respiratory system agents, Tumors -- Genetic aspects -- Drug therapy, Pharmaceutical industry, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Business, Gilotrif (Medication)
Abstract

M2 EQUITYBITES-January 17, 2018-Boehringer announces expanded indication for Gilotrif for NSCLC patients whose tumors have certain EGFR mutations (C)2018 M2 COMMUNICATIONS http://www.m2.com Pharmaceutical company Boehringer Ingelheim reported on Tuesday the [...]

Published
2018

64. Investigators at University Hospital Have Reported New Data on Small Cell Carcinoma (Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications)

Subjects
Chemotherapy, Respiratory system agents, Medical research, Carcinoma -- Genetic aspects -- Drug therapy, Epidermal growth factors, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Health
Abstract

2017 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Small Cell Carcinoma have been published. According to news reporting [...]

Published
2017

65. United States : TAGRISSO (AZD9291) approved by the US FDA for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer

Subjects
United States. Food and Drug Administration, AstraZeneca PLC, Small cell lung cancer -- Genetic aspects -- Drug therapy, Pharmaceutical industry, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Business, international
Abstract

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) [...]

Published
2015

66. TAGRISSO(TM) (osimertinib) (AZD9291) Approved By The US FDA As Treatment For Patients With EGFR T790M Mutation-Positive Metastatic Non-Small Cell Lung Cancer

Subjects
United States. Food and Drug Administration, AstraZeneca PLC, Small cell lung cancer -- Genetic aspects -- Drug therapy, Pharmaceutical industry, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Cancer metastasis -- Genetic aspects -- Drug therapy, Business, News, opinion and commentary
Abstract

One of fastest development programs - from start of clinical trials to approval in just over two and a half years to meet unmet patient need With objective response rate [...]

Published
2015

67. Researchers from Institute for Cancer Research and Treatment (IRCCS) Provide Details of New Studies and Findings in the Area of Small Cell Lung Cancer (Across the universe of K-RAS mutations in non-small-cell-lung cancer)

Subjects
Cancer research, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Proteins, Business, Health, Health care industry
Abstract

By a News Reporter-Staff News Editor at Cancer Weekly -- New research on Lung Diseases and Conditions is the subject of a report. According to news reporting from Milan, Italy, [...]

Published
2015

68. Study Data from Institute for Cancer Research and Treatment (IRCCS) Provide New Insights into Adenocarcinomas (Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of ...)

Subjects
Adenocarcinoma -- Genetic aspects -- Drug therapy, Cancer research, Non-small cell lung cancer -- Genetic aspects -- Drug therapy, Business, Health, Health care industry
Abstract

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Adenocarcinomas. According to news reporting from Reggio Emilia, Italy, by NewsRx journalists, research stated, 'Oncogenic [...]

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results